ArticleJournal of public health (Oxford, England)2026
Measuring performance in cancer services during COVID-19 and beyond: a novel case throughput metric using NHS Cancer Waiting Times data.
Article in Journal of public health (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer Waiting Times (CWT) targets are a central instrument of cancer policy in England, yet conventional performance indicators often obscure changes in service throughput. The COVID-19 pandemic exposed limitations in existing monitoring approaches, particularly for assessing disruption and recovery across cancer pathways.
methodsA novel case throughput metric (CTM) was developed by extracting National Health Service (NHS) England CWT data spanning 2017-23, covering 334 trusts and an average of 300 000 patients annually. The metric defines service throughput as the ratio of patient volumes meeting waiting time standards during defined periods of investigation normalized to a pre-pandemic baseline, enabling meaningful comparison across trusts while accounting for variation in trust sizes and pre-existing differences in service provision.
resultsThe metric revealed substantial heterogeneity in both disruption and recovery across cancer pathways, with diagnostic and referral routes experiencing greater and more persistent throughput loss than treatment pathways. Recovery trajectories also varied markedly between regions, with exploratory analyses suggesting associations with sociodemographic factors.
conclusionThe CTM provides a policy-relevant complement to existing CWT indicators by making changes in service throughput explicit. It offers a practical tool for monitoring cancer system resilience and informing recovery planning during and beyond major system shocks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.